Differential inhibitory effect of fondaparinux on the procoagulant potential of intact monocytes and monocyte-derived microparticles

Journal of Thrombosis and Thrombolysis

Volumn 30, Issue 4, 2010, Pages 412-418

  Ben Hadj Khalifa Kechiche, Sonia ^a,c   Hezard, Nathalie ^a,b   Poitevin, Stephane ^d   Remy, Marie Geneviève ^a   Florent, Bernadette ^a   Mahjoub, Touhami ^c   Nguyen, Philippe ^a,b  

^a SERVICE DE DERMATOLOGIE   (France)

^b Reims University Hospital   (France)

^c UNIVERSITY OF MONASTIR   (Tunisia)

^d INSERM   (France)

Author keywords

Fondaparinux; Monocyte; Monocyte derived microparticle; Thrombin generation; Tissue factor

Indexed keywords

ANTICOAGULANT AGENT; FONDAPARINUX; POLYSACCHARIDE; THROMBIN;

ADULT; ARTICLE; BLOOD; BLOOD CLOTTING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; MALE; MEMBRANE MICROPARTICLE; MONOCYTE; PHYSIOLOGY;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION; CELL-DERIVED MICROPARTICLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MONOCYTES; POLYSACCHARIDES; THROMBIN; YOUNG ADULT;

EID: 80053386838     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-010-0490-4     Document Type: Article

References (29)

1. Shantsila E, Lip GY (2009) Monocytes in acute coronary syndromes. Arterioscler Thromb Vasc Biol 29:1433-1438
2. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J (2005) Expansion of circulating toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 111:2654-2661
3. Leatham EW, Bath PM, Tooze JA, Camm AJ (1995) Increased monocyte tissue factor expression in coronary disease. Br Heart J 73:10-13
4. Ott I, Andrassy M, Zieglgansberger D, Geith S, Schomig A, Eumann FJ (2001) Regulation of monocyte procoagulant activity in acute myocardial infraction: Role of tissue factor and tissue factor pathway inhibitor-1. Blood 97:3721-3726
5. Matsumoto N, Nomura S, Kamihata H, Kimura Y, Iwasaka T (2004) Increased level of oxidized LDL-dependent monocytederived microparticles in acute coronary syndrome. Thromb Haemost 91:146-154
6. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A (1999) Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: A role for apoptosis in plaque thrombogenicity. Circulation 99:348-353
7. Leroyer AS, Isobe H, Leseche G, Castier Y, Wassef M, Mallat Z, Binder BR, Tedgui A, Boulanger CM (2007) Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 49:772-777
8. Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyongyo si M, Sperker W, Lass H, Mosgoeller W, Glogar DH, Probst P, Maurer G, Nemerson Y, Lang IM (2002) Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 99:2794-2800
9. Bauer KA (2004) Fondaparinux: A new synthetic and selective inhibitor of factor Xa. Best Pract Res Clin Haematol 17:89-104
10. Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP, Peters RJG, Budaj A, Afzal R, Chrolavicius S, Fox KAA, Yusuf S (2007) Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Results from the OASIS-5 trial. J Am Coll Cardiol 50:1742-1751
11. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJG, Bassand JP, Wallentin L, Joyner C, Fox KAA (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA 295:1519-1530
12. Nguyen P, Nguyen P, Broussas M, Cornillet-Lefebvre P, Potron G (1999) Coexpression of tissue factor and tissue factor pathway inhibitor by human monocytes purified by leukapheresis and elutriation. Response of nonadherent cells to lipopolysaccharide. Transfusion 39:975-982
13. Poitevin S, Cochery-Nouvellon E, Dupont A, Nguyen P (2007) Monocyte IL-10 produced in response to lipopolysaccharide modulates thrombin generation by inhibiting tissue factor expression and release of active tissue factor-bound microparticles. Thromb Haemost 97:598-607
14. Hemker HC, Giesen P, AlDieri R, Regnault V, Smed ED, Wagenvoord R, Lecompte T, Béguin S (2002) The calibrated automated thrombogram (CAT): A universal routine test for hyper-and hypocoagulability. Pathophysiol Haemost Thromb 32:249-253
15. Petros S, Siegemund T, Siegemund A, Engelmann L (2006) The effect of different anticoagulants on thrombin generation. Blood Coagul Fibrinolysis 17:131-137
16. Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM (2007) Effect of the anti-factor Xa and anti-factor IIa activities of lowmolecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 5:955-962
17. Robert S, Ghiotto J, Pirotte B, David JL, Masereel B, Pochet L, Dogné JM (2009) Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacol Res 59:160-166
18. Hemker HC, Beguin S (2000) Phenotyping the clotting system. Thromb Haemost 84:747-751
19. Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwege V, Hedman H, Freyssinet JM (1994) Monocyte vesiculation is a possible mechanism for dissemination of membraneassociated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 153:3245-3255
20. Biasucci LM, Biasillo G, Stefanelli A (2009) Procalcitonin and acute coronary syndromes: A new biomarker for old disease. Intern Emerg Med 4:363-365
21. Aharon A, Tamari T, Brenner B (2008) Monocyte-derived microparticles exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost 100:878-885
22. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA (2005) Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 106:1604-1611
23. Osterud B (2001) The role of platelets in decrypting monocyte tissue factor. Semin Hematol 38:2-5
24. Shaw AW, Pureza VS, Sligar SG, Morrissey JH (2007) The local phospholipid environment modulates the activation of blood clotting. J Biol Chem 282:6556-6563
25. Morrissey JH, Pureza V, Davis-Harrison RL, Sligar SG, Ohkubo YZ, Tajkhorshid E (2008) Blood clotting reactions on nanoscale phospholipid bilayers. Thromb Res 122:23-26
26. Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, Ruzyllo W, Umans VA, Vahanian A, Van De Werf F, Zeymer U, PENTUA Investigators (2004) A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) study. J Am Coll Cardiol 43:2183-2190
27. Turpie AG, Eriksson BI, Lassen MR, Bauer KA (2002) A metaanalysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc 11:182-188
28. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695-1702
29. Anderson JAM, Hirsh J, Yusuf S, Johnston M, Afzal R, Mehta SR, Fox KAA, Budaj A, Eikelboom JW (2010) Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organisation to assess strategies in acute ischemic syndromes (OASIS)-5 trial. J Thromb Haemost 8:243-249